Posted by Michael Wonder on 11 Feb 2019
Finch Therapeutics’ investigational drug CP101 granted breakthrough therapy designation from FDA for recurrent C. difficile infection
8 February 2019 - Designation to accelerate Finch’s efforts to provide an effective therapy for patients fighting recurrent C. difficile infection.
Finch Therapeutics today announced that the U.S. FDA has granted breakthrough therapy designation to investigational drug CP101 for the treatment of patients with recurrent Clostridium difficile (C. difficile) infection.
Finch is actively enrolling patients with recurrent C. difficile in PRISM3, a randomised, placebo-controlled Phase II clinical study to assess the safety and efficacy of CP101.
